Nutrition in adult patients with selected lysosomal storage diseases.

[1]  B. Bembi,et al.  Exercise training alone or in combination with high-protein diet in patients with late onset Pompe disease: results of a cross over study , 2020, Orphanet Journal of Rare Diseases.

[2]  C. Rodolico,et al.  Multisystem late onset Pompe disease (LOPD): an update on clinical aspects. , 2019, Annals of translational medicine.

[3]  L. Poll,et al.  Gaucher Disease in Bone: From Pathophysiology to Practice , 2019, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[4]  Maria Elisa Paiva Pires,et al.  Ketogenic Diet and Epilepsy: What We Know So Far , 2019, Front. Neurosci..

[5]  Á. Previdelli,et al.  Evaluation of food intake in patients with mucopolysaccharidosis , 2018, Nutrire.

[6]  W. Hwu,et al.  Recommendations for clinical monitoring of patients with acid sphingomyelinase deficiency (ASMD) , 2018, Molecular genetics and metabolism.

[7]  G. Barreto,et al.  The effect of fasting or calorie restriction on autophagy induction: A review of the literature , 2018, Ageing Research Reviews.

[8]  B. Davidson,et al.  Lysosomal storage diseases , 2018, Nature Reviews Disease Primers.

[9]  M. Sánchez-Niño,et al.  Enzyme replacement therapy dose and Fabry nephropathy , 2018, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[10]  A. Gasbarrini,et al.  Non-specific gastrointestinal features: Could it be Fabry disease? , 2018, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[11]  R. Schiffmann,et al.  Migalastat improves diarrhea in patients with Fabry disease: clinical-biomarker correlations from the phase 3 FACETS trial , 2018, Orphanet Journal of Rare Diseases.

[12]  C. Eng,et al.  Fabry disease revisited: Management and treatment recommendations for adult patients. , 2018, Molecular genetics and metabolism.

[13]  F. Nascimbeni,et al.  Energy balance, glucose and lipid metabolism, cardiovascular risk and liver disease burden in adult patients with type 1 Gaucher disease. , 2018, Blood cells, molecules & diseases.

[14]  J. Ibrahim,et al.  A pooled analysis of adverse events in 393 adults with Gaucher disease type 1 from four clinical trials of oral eliglustat: Evaluation of frequency, timing, and duration. , 2018, Blood cells, molecules & diseases.

[15]  S. McClave,et al.  Hypoalbuminemia and Clinical Outcomes: What is the Mechanism behind the Relationship? , 2017, The American surgeon.

[16]  P. Kaplan,et al.  Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry , 2017, American journal of hematology.

[17]  L. Al-Gazali,et al.  Pharmaceutical Chaperones and Proteostasis Regulators in the Therapy of Lysosomal Storage Disorders: Current Perspective and Future Promises , 2017, Front. Pharmacol..

[18]  K. Whelan,et al.  The low FODMAP diet: recent advances in understanding its mechanisms and efficacy in IBS , 2017, Gut.

[19]  D. Dumitrascu,et al.  Diet in irritable bowel syndrome: What to recommend, not what to forbid to patients! , 2017, World journal of gastroenterology.

[20]  B. Nur,et al.  Bone mineral density in patients with mucopolysaccharidosis type III , 2017, Journal of Bone and Mineral Metabolism.

[21]  David W. Johnson,et al.  Dietary interventions for adults with chronic kidney disease. , 2017, The Cochrane database of systematic reviews.

[22]  C. Cooper,et al.  UK clinical guideline for the prevention and treatment of osteoporosis , 2017, Archives of Osteoporosis.

[23]  S. Stirdivant,et al.  Serum global metabolomics profiling reveals profound metabolic impairments in patients with MPS IIIA and MPS IIIB , 2017, Metabolic Brain Disease.

[24]  M. Gelb,et al.  Newborn Screening for Lysosomal Storage Diseases: A Concise Review of the Literature on Screening Methods, Therapeutic Possibilities and Regional Programs , 2017, International journal of neonatal screening.

[25]  R. Schiffmann,et al.  Screening, diagnosis, and management of patients with Fabry disease: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. , 2017, Kidney international.

[26]  J. Stirnemann,et al.  A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments , 2017, International journal of molecular sciences.

[27]  O. Shirihai,et al.  Modulation of mTOR signaling as a strategy for the treatment of Pompe disease , 2017, EMBO molecular medicine.

[28]  D. Lockhart,et al.  Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study , 2016, Journal of Medical Genetics.

[29]  D. Lockhart,et al.  The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat , 2016, Genetics in Medicine.

[30]  H. Chung,et al.  β-Hydroxybutyrate suppresses inflammasome formation by ameliorating endoplasmic reticulum stress via AMPK activation , 2016, Oncotarget.

[31]  D. Hovda,et al.  Ketogenic diet decreases oxidative stress and improves mitochondrial respiratory complex activity , 2016, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[32]  D. Lockhart,et al.  Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat. , 2016, The New England journal of medicine.

[33]  R. Bazan,et al.  Enzyme replacement therapy for Anderson-Fabry disease. , 2016, The Cochrane database of systematic reviews.

[34]  L. Crocetti,et al.  CIRSE Standards of Practice Guidelines on Gastrostomy , 2016, CardioVascular and Interventional Radiology.

[35]  B. Kuo,et al.  Understanding the gastrointestinal manifestations of Fabry disease: promoting prompt diagnosis , 2016, Therapeutic advances in gastroenterology.

[36]  T. Uzu,et al.  Emerging role of mammalian autophagy in ketogenesis to overcome starvation , 2016, Autophagy.

[37]  M. Fuller,et al.  Selective normalisation of regional brain bis(monoacylglycero)phosphate in the mucopolysaccharidosis 1 (Hurler) mouse , 2016, Experimental Neurology.

[38]  Lichuan Yang,et al.  Effect of restricted protein diet supplemented with keto analogues in chronic kidney disease: a systematic review and meta-analysis , 2016, International Urology and Nephrology.

[39]  J. Marugan,et al.  Lysosomal storage and impaired autophagy lead to inflammasome activation in Gaucher macrophages , 2015, Aging cell.

[40]  P. Navas,et al.  Coenzyme Q10 and Pyridoxal Phosphate Deficiency Is a Common Feature in Mucopolysaccharidosis Type III. , 2015, JIMD reports.

[41]  P. Kaplan,et al.  The history and accomplishments of the ICGG Gaucher registry , 2015, American journal of hematology.

[42]  J. Pardo,et al.  Gastrointestinal symptoms in late-onset Pompe disease: Early response to enzyme replacement therapy , 2015, Journal of the Neurological Sciences.

[43]  M. Patterson,et al.  Stable or improved neurological manifestations during miglustat therapy in patients from the international disease registry for Niemann-Pick disease type C: an observational cohort study , 2015, Orphanet Journal of Rare Diseases.

[44]  A. Fellgiebel,et al.  Characterization of Early Disease Status in Treatment-Naive Male Paediatric Patients with Fabry Disease Enrolled in a Randomized Clinical Trial , 2015, PloS one.

[45]  S. Packman,et al.  Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease , 2015, Journal of Medical Genetics.

[46]  K. Nakanishi,et al.  Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: general therapy , 2015, Clinical and Experimental Nephrology.

[47]  A. Ballabio,et al.  Lysosomal storage diseases: from pathophysiology to therapy. , 2015, Annual review of medicine.

[48]  M. Poe,et al.  Early treatment is associated with improved cognition in Hurler syndrome , 2014, Annals of neurology.

[49]  D. Sabatini,et al.  Regulation of mTORC1 by amino acids. , 2014, Trends in cell biology.

[50]  Myung-Shik Lee,et al.  Autophagy—a key player in cellular and body metabolism , 2014, Nature Reviews Endocrinology.

[51]  D. Rosenthal,et al.  Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat , 2014, Skeletal Radiology.

[52]  A. Ribes,et al.  Treatment effect of coenzyme Q10 and an antioxidant cocktail in fibroblasts of patients with Sanfilippo disease , 2014, Journal of Inherited Metabolic Disease.

[53]  C. Lam,et al.  Differential Effects of FODMAPs (Fermentable Oligo-, Di-, Mono-Saccharides and Polyols) on Small and Large Intestinal Contents in Healthy Subjects Shown by MRI , 2013, The American Journal of Gastroenterology.

[54]  A. Levin,et al.  Practice Guideline , 2020, Encyclopedia of Behavioral Medicine.

[55]  J. Cichero,et al.  Thickening agents used for dysphagia management: effect on bioavailability of water, medication and feelings of satiety , 2013, Nutrition Journal.

[56]  D. Leucuta,et al.  Dynamic changes of lipid profile in Romanian patients with Gaucher disease type 1 under enzyme replacement therapy: a prospective study , 2013, Journal of Inherited Metabolic Disease.

[57]  L. Hobson‐Webb,et al.  Oropharyngeal dysphagia may occur in late-onset Pompe disease, implicating bulbar muscle involvement , 2013, Neuromuscular Disorders.

[58]  J. E. Wraith,et al.  Management of mucopolysaccharidosis type IH (Hurler’s syndrome) presenting in infancy with severe dilated cardiomyopathy: a single institution’s experience , 2013, Journal of Inherited Metabolic Disease.

[59]  N. Bresolin,et al.  Incontinence in Late-Onset Pompe Disease: An Underdiagnosed Treatable Condition , 2012, European Neurology.

[60]  C. Angelini,et al.  The role of autophagy in the pathogenesis of glycogen storage disease type II (GSDII) , 2012, Cell Death and Differentiation.

[61]  A. Ballabio,et al.  Autophagy in lysosomal storage disorders , 2012, Autophagy.

[62]  C. Angelini,et al.  Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years , 2012, Journal of Neurology.

[63]  A. Salminen,et al.  Mitochondrial dysfunction and oxidative stress activate inflammasomes: impact on the aging process and age-related diseases , 2012, Cellular and Molecular Life Sciences.

[64]  Jay J. Han,et al.  Consensus treatment recommendations for late‐onset Pompe disease , 2012, Muscle & nerve.

[65]  E. Ralston,et al.  Autophagy and mitochondria in Pompe disease: Nothing is so new as what has long been forgotten , 2012, American journal of medical genetics. Part C, Seminars in medical genetics.

[66]  Claude Pichard,et al.  The Evaluation of Body Composition: A Useful Tool for Clinical Practice , 2011, Annals of Nutrition and Metabolism.

[67]  V. Valayannopoulos,et al.  Therapy for the mucopolysaccharidoses. , 2011, Rheumatology.

[68]  J. Muenzer.  Overview of the mucopolysaccharidoses. , 2011, Rheumatology.

[69]  P. V. van Doorn,et al.  Facial-muscle weakness, speech disorders and dysphagia are common in patients with classic infantile Pompe disease treated with enzyme therapy , 2011, Journal of Inherited Metabolic Disease.

[70]  C. Hendriksz,et al.  Gastrointestinal disturbances and their management in miglustat-treated patients , 2011, Journal of Inherited Metabolic Disease.

[71]  P. Mistry,et al.  Evaluation of high density lipoprotein as a circulating biomarker of Gaucher disease activity , 2011, Journal of Inherited Metabolic Disease.

[72]  C. Netto,et al.  Gaucher disease type I: assessment of basal metabolic rate in patients from southern Brazil. , 2011, Blood cells, molecules & diseases.

[73]  D. Germain.  Fabry disease , 2010, Orphanet journal of rare diseases.

[74]  M. Fuller.  Sphingolipids: the nexus between Gaucher disease and insulin resistance , 2010, Lipids in Health and Disease.

[75]  R. Desnick,et al.  Pompe disease: dramatic improvement in gastrointestinal function following enzyme replacement therapy. A report of three later-onset patients. , 2010, Molecular genetics and metabolism.

[76]  R. Lachmann,et al.  Dietary modifications in patients receiving miglustat , 2010, Journal of Inherited Metabolic Disease.

[77]  W. Hop,et al.  Low bone mass in Pompe disease: muscular strength as a predictor of bone mineral density. , 2010, Bone.

[78]  J. Dziura,et al.  High incidence of cholesterol gallstone disease in type 1 Gaucher disease: characterizing the biliary phenotype of type 1 Gaucher disease , 2010, Journal of Inherited Metabolic Disease.

[79]  P. Saftig,et al.  Lysosome biogenesis and lysosomal membrane proteins: trafficking meets function , 2009, Nature Reviews Molecular Cell Biology.

[80]  M. Sands,et al.  Metabolic Adaptations to Interrupted Glycosaminoglycan Recycling* , 2009, The Journal of Biological Chemistry.

[81]  J. Kastelein,et al.  Low HDL cholesterol levels in type I Gaucher disease do not lead to an increased risk of cardiovascular disease. , 2009, Atherosclerosis.

[82]  J. E. Wraith,et al.  Mucopolysaccharidosis I: Management and Treatment Guidelines , 2009, Pediatrics.

[83]  A. Reuser,et al.  Pompe's disease , 2008, The Lancet.

[84]  Y. Bayraktar,et al.  Gaucher disease: new developments in treatment and etiology. , 2008, World journal of gastroenterology.

[85]  J. M. Aerts,et al.  Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring , 2008, Journal of Inherited Metabolic Disease.

[86]  D. Goldsmith,et al.  Nephrotic syndrome in adults , 2008, BMJ : British Medical Journal.

[87]  J. M. Aerts,et al.  Overweight, insulin resistance and type II diabetes in type I Gaucher disease patients in relation to enzyme replacement therapy. , 2008, Blood cells, molecules & diseases.

[88]  P. Kaplan,et al.  Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study , 2008, Clinical genetics.

[89]  J. M. Aerts,et al.  Type I Gaucher disease, a glycosphingolipid storage disorder, is associated with insulin resistance. , 2008, The Journal of clinical endocrinology and metabolism.

[90]  L. Clarke.  The mucopolysaccharidoses: a success of molecular medicine , 2008, Expert Reviews in Molecular Medicine.

[91]  A. Mehta,et al.  Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[92]  M. Patterson,et al.  Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study , 2007, The Lancet Neurology.

[93]  J. Stevens,et al.  Continuous ambulatory peritoneal dialysis patients are unable to increase dietary intake to recommended levels. , 2007, Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation.

[94]  C. Coldéa,et al.  Outcome of enzyme replacement therapy in patients with Gaucher disease type I. The Romanian experience , 2007, Journal of Inherited Metabolic Disease.

[95]  N. Raben,et al.  Role of autophagy in the pathogenesis of Pompe disease. , 2007, Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology.

[96]  J. Cichero,et al.  Texture-modified foods and thickened fluids as used for individuals with dysphagia: Australian standardised labels and definitions , 2007 .

[97]  Joseph Muenzer,et al.  The MPS I registry: design, methodology, and early findings of a global disease registry for monitoring patients with Mucopolysaccharidosis Type I. , 2007, Molecular genetics and metabolism.

[98]  M. Langeveld,et al.  Very low serum adiponectin levels in patients with type 1 Gaucher disease without overt hyperglycemia. , 2007, Metabolism: clinical and experimental.

[99]  J. Galanko,et al.  Modification of the natural history of adult‐onset acid maltase deficiency by nutrition and exercise therapy , 2007, Muscle & nerve.

[100]  S. Brodie,et al.  Acid sphingomyelinase deficiency: prevalence and characterization of an intermediate phenotype of Niemann-Pick disease. , 2006, The Journal of pediatrics.

[101]  S. Brodie,et al.  Fabry disease: Guidelines for the evaluation and management of multi-organ system involvement , 2006, Genetics in Medicine.

[102]  A. Pichiecchio,et al.  Dietary treatment in adult-onset type II glycogenosis , 2006, Journal of inherited metabolic disease.

[103]  David M. Rapoport,et al.  Pompe disease diagnosis and management guideline , 2006, Genetics in Medicine.

[104]  Y. Ioannou.  Guilty until proven innocent: the case of NPC1 and cholesterol. , 2005, Trends in biochemical sciences.

[105]  Charlene Compher,et al.  Comparison of predictive equations for resting metabolic rate in healthy nonobese and obese adults: a systematic review. , 2005, Journal of the American Dietetic Association.

[106]  P. Kaplan,et al.  Individualization of long-term enzyme replacement therapy for Gaucher disease , 2005, Genetics in Medicine.

[107]  S. Hossain,et al.  The Natural History of Type B Niemann-Pick Disease: Results From a 10-Year Longitudinal Study , 2004, Pediatrics.

[108]  G. Andria,et al.  Therapeutic goals in the treatment of Gaucher disease. , 2004, Seminars in hematology.

[109]  G. Dallner,et al.  Metabolism and function of coenzyme Q. , 2004, Biochimica et biophysica acta.

[110]  M. Vanier.  Niemann-Pick disease type C , 2010, Orphanet journal of rare diseases.

[111]  C. Peters,et al.  Hematopoietic cell transplantation for inherited metabolic diseases: an overview of outcomes and practice guidelines , 2003, Bone Marrow Transplantation.

[112]  O. Bodamer,et al.  L-alanine supplementation in late infantile glycogen storage disease type II. , 2002, Pediatric neurology.

[113]  S. Walkley,et al.  Critical role for glycosphingolipids in Niemann-Pick disease type C , 2001, Current Biology.

[114]  M. Patterson,et al.  Niemann-Pick C variant detection by altered sphingolipid trafficking and correlation with mutations within a specific domain of NPC1. , 2001, American journal of human genetics.

[115]  O. Bodamer,et al.  The effects of l-alanine supplementation in late-onset glycogen storage disease type II , 2000, Neurology.

[116]  P. Meikle,et al.  Prevalence of lysosomal storage disorders. , 1999, JAMA.

[117]  J. Romijn,et al.  Differential effects of enzyme supplementation therapy on manifestations of type 1 Gaucher disease. , 1997, The American journal of medicine.

[118]  O. Bodamer,et al.  Dietary treatment in late-onset acid maltase deficiency , 1997, European Journal of Pediatrics.

[119]  N. LeLeiko,et al.  Resting energy expenditure in Gaucher's disease type 1: effect of Gaucher's cell burden on energy requirements. , 1989, Metabolism: clinical and experimental.

[120]  H. Ginsberg,et al.  Abnormalities in lipoprotein metabolism in Gaucher type 1 disease. , 1988, Metabolism: clinical and experimental.

[121]  R. Fagerstrom,et al.  Reduced plasma concentrations of total, low density lipoprotein and high density lipoprotein cholesterol in patients with Gaucher type I disease , 1984, Clinical genetics.

[122]  C. Gallegos,et al.  Nutritional Aspects of Dysphagia Management. , 2017, Advances in food and nutrition research.

[123]  R. Desnick,et al.  Types A and B Niemann-Pick disease. , 2017, Molecular genetics and metabolism.

[124]  P. Maison-Blanche,et al.  Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe. , 2017, European journal of internal medicine.

[125]  J. Seppen,et al.  Adverse Effects of Genistein in a Mucopolysaccharidosis Type I Mouse Model. , 2015, JIMD reports.

[126]  A. Nagral.  Gaucher disease. , 2014, Journal of clinical and experimental hepatology.

[127]  M. Vorgerd,et al.  Urge incontinence and gastrointestinal symptoms in adult patients with pompe disease: a cross-sectional survey. , 2014, JIMD reports.

[128]  M. Vanier.  Niemann-Pick diseases. , 2013, Handbook of clinical neurology.

[129]  S. Akman,et al.  A cross-sectional, mono-centric pilot study of insulin resistance in enzyme replacement therapy patients with Gaucher type I without overweight. , 2009, Molecular genetics and metabolism.

[130]  S. Keshav.  Gastrointestinal manifestations of Fabry disease , 2006 .

[131]  J. Kopple,et al.  National kidney foundation K/DOQI clinical practice guidelines for nutrition in chronic renal failure. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.